Navigation Links
TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials

e viral load (less than 50 copies/mL), compared with those in the placebo arm (39 percent; n=119) [p=0.005]. Similarly, in DUET-2, significantly more patients (62 percent; n=183) in the TMC125 arm achieved a confirmed undetectable viral load compared with those in the placebo arm (44 percent; n=129) [p=0.0003].

"The NNRTI class has been one of the cornerstones of antiretroviral therapy for more than a decade. However, NNRTI resistance limits the use of this class in treatment-experienced patients," said Tony Mills, MD, HIV specialist in private practice, Los Angeles, and assistant professor of clinical medicine, UCLA. "The results that we saw in DUET-1 and -2 in patients with documented NNRTI resistance are very exciting and suggest that in the future, we may have the ability to sequence NNRTIs in HIV treatment."

24-Week Safety Findings

In DUET-1, the most commonly reported adverse events (>=10%), regardless of causality, among patients in the TMC125 arm vs. placebo arm were rash (20 percent vs. 10 percent), nausea (14 percent vs. 12 percent), diarrhea (12 percent vs. 20 percent), headache (10 percent vs. 13 percent), nervous system disorders including headache, somnolence, dizziness, and memory impairment (15 percent vs. 20 percent), and psychiatric disorders including insomnia, anxiety, depression and nightmare (10 percent vs. 14 percent). In the TMC125 arm, 42 patients discontinued treatment for any reason vs. 56 patients in the placebo arm.

In DUET-2, the most commonly reported adverse events (>=10%), regardless of causality, among patients receiving TMC125 vs. placebo were rash (14 percent vs. 9 percent), diarrhea (18 percent vs. 20 percent), nausea (14 percent vs. 10 percent), injection site reaction (13 percent vs. 15 percent), headache (9 percent vs. 11 percent), fatigue (9 percent vs. 10 percent), nervous system disorders (15 percent vs. 17 percent) and psychiatric disorders (16 percent vs. 17 percent). In the TMC125 arm, 51 pati
'"/>




Page: 1 2 3 4

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
5. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
6. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
7. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
8. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
9. Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
10. OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
11. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
Post Your Comments:
(Date:9/29/2014)... SAN DIEGO , 29. ... Ltd. (nachstehend Daiichi Sankyo) (TSE: 4568) und ... gaben heute gemeinsam eine definitive Fusionsvereinbarung bekannt, ... von Ambit Biosciences für 15 US-Dollar je ... anschließenden Zusammenschluss mit einem Tochterunternehmen von Daiichi ...
(Date:9/29/2014)... IRVING, Texas , Sept. 29, 2014 /PRNewswire/ ... 340B Drug Pricing Program, has announced that it ... Services Administration (HRSA) to continue serving in its ... 2019. Apexus, which has held this position for ... with more than 25,000 safety-net provider locations, drug ...
(Date:9/29/2014)... SEATTLE , Sept. 29, 2014 ... leverages Next Generation Sequencing to profile the adaptive ... a Scientific Advisory Board to provide strategic and ... diagnostic suite of assays in the diagnosis and ... initial focus of the SAB will be to ...
Breaking Medicine Technology:Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Apexus Wins HRSA Contract to Remain Prime Vendor of 340B Program 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3
... Medical Inc. (TMI),announced today that it has been ... commercialize in Europe the Antares(TM) Coronary,Stent System, a ... use,at or near coronary bifurcations., Representing the ... potential use in a quarter of the 2.2 ...
... Line Clinical Results Expected in November 2008, BOTHELL, ... ) announced today the completion of patient enrollment and ... evaluate the safety and,efficacy of its formulation of 12-hour ... expects to report top-line,results from this pivotal trial in ...
Cached Medicine Technology:TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3
(Date:9/30/2014)... KY (PRWEB) September 30, 2014 Up ... people in the United States alone have sleep apnea. ... and of those treated, many cannot tolerate their prescribed ... supplied through a nasal mask) – which supports the ... night’s sleep has become especially valuable, and increasingly difficult ...
(Date:9/30/2014)... compared with placebo did not reduce hospital length of ... mortality, or the risk of death at 6 months ... ill, according to a study published in JAMA ... coincide with its presentation at the European Society of ... prevalence of low vitamin D levels has been confirmed ...
(Date:9/30/2014)... Youth Town’s annual BBQ/Music Festival will take ... p.m. at the Youth Town campus (3641 Youth Town ... family-oriented festival, which will offer music, food and games. ... car show, arts and crafts fair, music, championship barbeque ... Lightning McQueen and Mater from the hit Disney movie ...
(Date:9/30/2014)... September 30, 2014 Top10inaction.com, one of ... on ranking and reviewing all essential categories in daily ... announced the best liquid foundation at http://top10inaction.com/liquid-foundations/ , ... is named as the best foundation of them all. ... well as high end brands, hence customers have more ...
(Date:9/30/2014)... September 30, 2014 3M has added four ... high bond tapes. 3M 5906 , 3M 5907 ... are conformable VHBs which help create the strongest bond possible ... are used for bonding to difficult surfaces such as paints, ... 5906, 5907, 5908, and 5905 are designed specifically for electronic ...
Breaking Medicine News(10 mins):Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2Health News:Yves Saint Laurent is Named As Best Liquid Foundation 2014 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3
... The University of Pittsburgh Cancer Institute (UPCI) today ... F. Shapira BRCA Cancer Research Program. BRCA 1 and ... the risk of breast, prostate, ovarian and pancreatic cancers. ... this research program to UPCI, said Ronald Herberman, M.D., ...
... people on trial were granted the right to an interpreter ... by UCL (University College London) scientists. The use of family ... teachers and eventually written testimony, which may have disadvantaged the ... British Sign Language was emerging. , The study, ...
... debt and expands available credit facility, HATBORO, ... leading technology provider of enterprise mobility solutions for,the ... has,completed a senior debt financing of up to ... HTGC )., (Logo: http://www.newscom.com/cgi-bin/prnh/20071101/NETH165LOGO ...
... country and online offer opportunity to save a life, ... of adding,46,000 new members to the marrow Registry during ... Marrow Donor Program,s largest,annual awareness campaign, kicks off today., ... other,life-threatening diseases, a marrow transplant offers a second chance ...
... and atypical cells also indicate high risk of second cancer, study ... have been diagnosed with breast cancer, having a known mutation in ... second cancer, and many of these women choose to have their ... However, new research suggests that women who don,t have ...
... May 5 Facet Solutions, Inc., a privately,held ... announced the successful completion of a scientific,evaluation for ... The study,evaluated the combination of Facet Solutions, Anatomic ... device in a,finite element model. The details of ...
Cached Medicine News:Health News:Research program focuses on genetic mutations and cancer risk 2Health News:'Deaf by God' tried in Old Bailey records 2Health News:'Deaf by God' tried in Old Bailey records 3Health News:InfoLogix Completes $25 Million Senior Debt Financing 2Health News:InfoLogix Completes $25 Million Senior Debt Financing 3Health News:National Marrow Donor Program(R) Kicks off National Awareness Campaign 2Health News:National Marrow Donor Program(R) Kicks off National Awareness Campaign 3Health News:BRCA Mutations Don't Spot All High-Risk Women 2Health News:BRCA Mutations Don't Spot All High-Risk Women 3Health News:Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study 2
Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 3 mm x 1.0 mm x 3.0 mm....
Medicine Products: